MedTrace Logo

Study of the Effects of Yerba Mate on Cardiometabolic Health

NCT06729905 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-05-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if consuming a beverage prepared with yerba mate leaves helps to improve blood lipid levels in persons at high cardiovascular risk. It will also learn about the effects of this beverage, widely consumed in South America, on other cardiometabolic biomarkers like blood glucose levels, inflammation, or weight control. The main questions it aims to answer are:

Does daily consumption of a yerba mate tea reduce the blood lipid levels in hypercholesterolemic persons? May healthy persons also benefit from the consumption of yerba mate tea?

Researchers will compare yerba mate to a control drink (isotonic drink or water, free of polyphenols and caffeine) to see if yerba mate tea helps to reduce blood cholesterol in hypercholesterolemic persons.

Participants will:

Drink 3 cups of yerba mate tea or an isotonic drink every day for 2 months, then change to the other drink during another 2 months.

Visit the clinic at the beginning and end of each 2-month period for checkups and tests Refraing from consuming coffee and some foods during the study. Complete a dietary questionnaire during 3 days before each visit to the clinic.

Conditions

  • Cardiovascular Risk
  • Hypercholerolemia

Interventions

DIETARY_SUPPLEMENT

Yerba mate tea

Consumption of three cups per day of a beverage prepared with yerba mate

DIETARY_SUPPLEMENT

Control drink

Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.

Sponsors & Collaborators

  • Ministry of Science and Innovation, Spain

    collaborator OTHER_GOV

  • Instituto de Ciencia y Tecnología de Alimentos y Nutrición

    lead OTHER_GOV

Principal Investigators

  • Laura Bravo, Professor · ICTAN-CSIC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-10
Primary Completion
2013-07-30
Completion
2015-05-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06729905 on ClinicalTrials.gov